Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardiometabolic health measures. She described the novel drug as a potential highly impactful tool to treat patients living with obesity and transform their health trajectory.
Science 2007;317:477
- After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly
WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk
EazeTab offers clear, monthly self-pay pricing for GLP-1 therapies (Rx only): First month Semaglutide ODT $299, Tirzepatide ODT $299 Ongoing monthly Semaglutide ODT $349, Tirzepatide ODT $349 Your $150 reservation fee is credited toward your first prescription, less applicable fees
Some owners report their dogs moving more freely after a course of treatment, even without changes to the joint itself
